Why Neurocrine is charging twice as much for its new drug as it said it would

Short resume:

patients
90%
market
90%
marketwatch
90%
data
70%

When Neurocrine Biosciences’ drug Ingrezza was first approved last month, the company announced that the $64,000-a-year price tag would be “essentially the same” at different dose levels so patients could focus on their treatment, not on cost.
Source MarketWatch
Read More…

More News

Be the first to comment

Leave a Reply

Your email address will not be published.


*